Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amisulpride Injection for Prevention of Postoperative Nausea and Vomiting
CTR20230868Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of amisulpride in postoperative nausea and vomiting (PONV), sponsored by Qilu Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on CTR20230868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230868.